一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Cancer treatment reviews >>article
Cancer treatment reviews

Cancer treatment reviews

IF: 9.59
Download PDF

EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins

Published:1 November 2020 DOI: 10.1016/j.ctrv.2020.102105 PMID: 32979839
Jordi Remon , Lizza E.L. Hendriks , Andres F. Cardona , Benjamin Besse

Abstract

Although targeted therapy is standard of care in a large subset of oncogenic addicted non-small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been feasible for all genomic alterations such as for those tumors harboring Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations. Despite being the third most common EGFR mutation, a limited efficacy of first- and second-generation EGFR tyrosine kinase inhibitors (TKI) exists. This is related to the heterogeneity at the molecular level in EGFR ex20ins mutation variants and the finding that this mutation promotes active kinase conformation but does not increase the affinity for EGFR TKI. As a result, the prognosis of this population is diminished. Therefore, chemotherapy remained the most suitable strategy in this subset of EGFR mutant NSCLC patients. Recently, new treatment strategies have been reported in this landscape, either with new EGFR TKI or bispecific antibodies, which may establish a new standard of care in the coming future for these patients. Future research should focus on elucidating the oncogenic degree of all EGFR ex20ins variants, the potential role of combination strategies either with chemotherapy or immune checkpoint inhibitors, and the most appropriate first-line treatment strategy in this subgroup. Finally, the knowledge of mechanisms of acquired resistance to these new agents upon progression is a priority for personalising treatment at that time. It is in this framework, that we provide a thorough overview on this subject.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
EGFR-HER2 Ex20Ins inhibitor 1a 2068806-31-3 C25H22FN7O3 22 suppliers Inquiry
Kinase inhibitor-1 2135696-72-7 C19H18BrClN6O 21 suppliers Inquiry
EGFR 11 suppliers Inquiry

Similar articles

IF:3

A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer

Saudi Pharmaceutical Journal Silky Bedi , Shah A. Khan ,etc Published: 1 September 2018
IF:12.7

Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.

ACS Central Science Sabrina Baltschukat, Barbara Schacher Engstler,etc Published: 15 May 2019
来宾市| 大方县| 驻马店市| 新密市| 深圳市| 南宁市| 泾源县| 大兴区| 九龙坡区| 子长县| 金乡县| 郯城县| 长治县| 禄丰县| 基隆市| 阿城市| 金阳县| 报价| 南通市| 马山县| 旬阳县| 灵璧县| 连州市| 永仁县| 咸阳市| 萝北县| 鸡东县| 芮城县| 栾城县| 正安县| 偃师市| 高碑店市| 图们市| 民和| 金沙县| 茂名市| 南和县| 高要市| 辛集市| 惠州市| 东乡族自治县|